

**TDMS No.** 20516 - 01

**Test Type:** 90-DAY

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** RATS/F344/N Tac

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim SC210)

**CAS Number:** TRIMSC210

**Date Report Requested:** 08/25/2008

**Time Report Requested:** 10:19:53

**First Dose M/F:** 08/14/06 / 08/14/06

**Lab:** BNW

F1\_RD

**C Number:** C20516  
**Lock Date:** 05/16/2007  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.0.0

TDMS No. 20516 - 01

Test Type: 90-DAY

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: RATS/F344/N Tac

**P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS**

Metal working fluids (Trim SC210)

CAS Number: TRIMSC210

Date Report Requested: 08/25/2008

Time Report Requested: 10:19:53

First Dose M/F: 08/14/06 / 08/14/06

Lab: BNW

**SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Metal working fluids (Trim SC210)**

**MALE RATS**

**Organ**

Larynx

Larynx: Squamous Epithelium

Liver

Lung

Lung: Alveolus

Nose: Goblet Cell

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

**Morphology**

Inflammation Acute

Inflammation Chronic

Metaplasia

Ulcer

Hyperplasia

Hepatodiaphragmatic Nodule

Inflammation Chronic

Metaplasia Osseous

Infiltration Cellular Histiocyte

Hyperplasia

Accumulation, Hyaline Droplet

Inflammation

Accumulation, Hyaline Droplet

Inflammation

**FEMALE RATS**

**Organ**

Larynx

Larynx: Squamous Epithelium

Liver

Lung

Lung: Alveolus

Lung: Arteriole

Nose: Goblet Cell

Nose: Olfactory Epithelium

Nose: Respiratory Epithelium

Ovary

**Morphology**

Inflammation Chronic

Metaplasia

Hyperplasia

Hepatodiaphragmatic Nodule

Inflammation Chronic

Inflammation Chronic

Infiltration Cellular Histiocyte

Mineralization

Hyperplasia

Accumulation, Hyaline Droplet

Inflammation

Accumulation, Hyaline Droplet

Inflammation

Cyst

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Harderian Gland  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	10%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.377N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Heart  
Cardiomyopathy**

**LESION RATES**

OVERALL (a)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	8/10 (80%)
POLY-3 RATE (b)	9/10.00	0/0.00	0/0.00	0/0.00	0/0.00	8/10.00
POLY-3 PERCENT (g)	90%	0%	0%	0%	0%	80%
TERMINAL (d)	9/10 (90%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	8/10 (80%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.377N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Intestine Large, Rectum: Arteriole  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	20%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.702
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.702
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.702
COCH-ARM / FISHERS	P=0.610	(e)	(e)	(e)	(e)	P=0.709N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Kidney  
Nephropathy**

**LESION RATES**

OVERALL (a)	7/10 (70%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
POLY-3 RATE (b)	7/10.00	0/0.00	0/0.00	0/0.00	0/0.00	6/10.00
POLY-3 PERCENT (g)	70%	0%	0%	0%	0%	60%
TERMINAL (d)	7/10 (70%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/10 (60%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.407N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.325N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Erosion**

**LESION RATES**

OVERALL (a)	2/10 (20%)	0/10 (0%)	2/10 (20%)	1/10 (10%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	2/10.00	0/10.00	2/10.00	1/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	20%	0%	20%	10%	0%	0%
TERMINAL (d)	2/10 (20%)	0/10 (0%)	2/10 (20%)	1/10 (10%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	93 (T)	93 (T)	---	---

**STATISTICAL TESTS**

POLY 3	P=0.119N	P=0.227N	P=0.702	P=0.500N	P=0.227N	P=0.227N
POLY 1.5	P=0.119N	P=0.227N	P=0.702	P=0.500N	P=0.227N	P=0.227N
POLY 6	P=0.119N	P=0.227N	P=0.702	P=0.500N	P=0.227N	P=0.227N
COCH-ARM / FISHERS	P=0.120N	P=0.237N	P=0.709N	P=0.500N	P=0.237N	P=0.237N
MAX-ISO-POLY-3	P=0.052N	P=0.066N	P=1.000	P=0.274N	P=0.066N	P=0.066N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Inflammation Acute**

**LESION RATES**

OVERALL (a)	4/10 (40%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	4/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	40%	0%	0%	0%	0%	0%
TERMINAL (d)	4/10 (40%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	---	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.032N*	P=0.033N*	P=0.033N*	P=0.033N*	P=0.033N*	P=0.033N*
POLY 1.5	P=0.032N*	P=0.033N*	P=0.033N*	P=0.033N*	P=0.033N*	P=0.033N*
POLY 6	P=0.032N*	P=0.033N*	P=0.033N*	P=0.033N*	P=0.033N*	P=0.033N*
COCH-ARM / FISHERS	P=0.058N	P=0.043N*	P=0.043N*	P=0.043N*	P=0.043N*	P=0.043N*
MAX-ISO-POLY-3	P<0.001N**	P=0.007N**	P=0.007N**	P=0.007N**	P=0.007N**	P=0.007N**



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/10 (0%)	6/10 (60%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	6/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	60%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	6/10 (60%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.005**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Metaplasia**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Ulcer**

**LESION RATES**

OVERALL (a)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	2/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	0%
TERMINAL (d)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	93 (T)	---	---	---	---	---

**STATISTICAL TESTS**

POLY 3	P=0.193N	P=0.227N	P=0.227N	P=0.227N	P=0.227N	P=0.227N
POLY 1.5	P=0.193N	P=0.227N	P=0.227N	P=0.227N	P=0.227N	P=0.227N
POLY 6	P=0.193N	P=0.227N	P=0.227N	P=0.227N	P=0.227N	P=0.227N
COCH-ARM / FISHERS	P=0.203N	P=0.237N	P=0.237N	P=0.237N	P=0.237N	P=0.237N
MAX-ISO-POLY-3	P=0.005N**	P=0.066N	P=0.066N	P=0.066N	P=0.066N	P=0.066N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx: Squamous Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	4/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	40%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	---	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.033*	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.043*	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.007**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver  
Hepatodiaphragmatic Nodule**

**LESION RATES**

OVERALL (a)	0/10 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	1/1.00	0/0.00	1/1.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	100%	0%	100%	0%	10%
TERMINAL (d)	0/10 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	---	93 (T)	---	93 (T)	---	93 (T)

**STATISTICAL TESTS**

POLY 3	(e)	P=0.091	(e)	P=0.091	(e)	P=0.500
POLY 1.5	(e)	P=0.091	(e)	P=0.091	(e)	P=0.500
POLY 6	(e)	P=0.091	(e)	P=0.091	(e)	P=0.500
COCH-ARM / FISHERS	P=0.579N	P=0.091	(e)	P=0.091	(e)	P=0.500
MAX-ISO-POLY-3	(e)	P<0.001**	(e)	P<0.001**	(e)	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	7/10 (70%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/0 (0%)	4/10 (40%)
POLY-3 RATE (b)	7/10.00	0/1.00	0/0.00	0/1.00	0/0.00	4/10.00
POLY-3 PERCENT (g)	70%	0%	0%	0%	0%	40%
TERMINAL (d)	7/10 (70%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/0 (0%)	4/10 (40%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

**STATISTICAL TESTS**

POLY 3	(e)	P=0.384N	(e)	P=0.384N	(e)	P=0.186N
POLY 1.5	(e)	P=0.384N	(e)	P=0.384N	(e)	P=0.186N
POLY 6	(e)	P=0.384N	(e)	P=0.384N	(e)	P=0.186N
COCH-ARM / FISHERS	P=0.214N	P=0.364N	(e)	P=0.364N	(e)	P=0.185N
MAX-ISO-POLY-3	(e)	P=0.152N	(e)	P=0.152N	(e)	P=0.089N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	9/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	90%	100%	100%	100%	100%	100%
TERMINAL (d)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P=0.416	P=0.500	P=0.500	P=0.500	P=0.500	P=0.500
POLY 1.5	P=0.416	P=0.500	P=0.500	P=0.500	P=0.500	P=0.500
POLY 6	P=0.416	P=0.500	P=0.500	P=0.500	P=0.500	P=0.500
COCH-ARM / FISHERS	P=0.415	P=0.500	P=0.500	P=0.500	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.041*	P=0.158	P=0.158	P=0.158	P=0.158	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung  
Metaplasia Osseous**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	1/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	0%	0%	0%	10%	0%	20%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE	---	---	---	93 (T)	---	93 (T)

**STATISTICAL TESTS**

POLY 3	P=0.036*	(e)	(e)	P=0.500	(e)	P=0.227
POLY 1.5	P=0.036*	(e)	(e)	P=0.500	(e)	P=0.227
POLY 6	P=0.036*	(e)	(e)	P=0.500	(e)	P=0.227
COCH-ARM / FISHERS	P=0.038*	(e)	(e)	P=0.500	(e)	P=0.237
MAX-ISO-POLY-3	P=0.019*	(e)	(e)	P=0.158	(e)	P=0.066



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung: Alveolus  
Infiltration Cellular Histiocyte**

**LESION RATES**

OVERALL (a)	0/10 (0%)	2/10 (20%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	2/10.00	0/10.00	0/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	20%	0%	0%	100%	100%
TERMINAL (d)	0/10 (0%)	2/10 (20%)	0/10 (0%)	0/10 (0%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	---	---	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.227	(e)	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.227	(e)	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.227	(e)	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.237	(e)	(e)	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.066	(e)	(e)	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung: Arteriole  
Mineralization**

**LESION RATES**

OVERALL (a)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	2/10.00	0/10.00	0/10.00	0/10.00	0/10.00	2/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	20%
TERMINAL (d)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

**STATISTICAL TESTS**

POLY 3	P=0.239	P=0.227N	P=0.227N	P=0.227N	P=0.227N	P=0.702
POLY 1.5	P=0.239	P=0.227N	P=0.227N	P=0.227N	P=0.227N	P=0.702
POLY 6	P=0.239	P=0.227N	P=0.227N	P=0.227N	P=0.227N	P=0.702
COCH-ARM / FISHERS	P=0.245	P=0.237N	P=0.237N	P=0.237N	P=0.237N	P=0.709N
MAX-ISO-POLY-3	P=0.070	P=0.066N	P=0.066N	P=0.066N	P=0.066N	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Goblet Cell  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium  
Inflammation**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium  
Inflammation**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	93 (T)	93 (T)	93 (T)	93 (T)	93 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Pancreas  
Atrophy**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Trachea  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
POLY-3 RATE (b)	1/10.00	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	10%
TERMINAL (d)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
FIRST INCIDENCE	93 (T)	---	---	---	---	93 (T)

**STATISTICAL TESTS**

POLY 3	P=0.415	P=0.500N	P=0.500N	P=0.500N	P=0.500N	P=0.760
POLY 1.5	P=0.415	P=0.500N	P=0.500N	P=0.500N	P=0.500N	P=0.760
POLY 6	P=0.415	P=0.500N	P=0.500N	P=0.500N	P=0.500N	P=0.760
COCH-ARM / FISHERS	P=0.414	P=0.500N	P=0.500N	P=0.500N	P=0.500N	P=0.763N
MAX-ISO-POLY-3	P=0.163	P=0.158N	P=0.158N	P=0.158N	P=0.158N	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Harderian Gland  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	0/0.00	2/10.00
POLY-3 PERCENT (g)	10%	0%	0%	0%	0%	20%
TERMINAL (d)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/10 (20%)
FIRST INCIDENCE	94 (T)	---	---	---	---	94 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.377	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Heart  
Cardiomyopathy**

**LESION RATES**

OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	10%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	94 (T)	---	---	---	---	94 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.377N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.274N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Intestine Large, Rectum: Arteriole  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	94 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.304	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Kidney  
Nephropathy**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/0.00	0/0.00	0/0.00	0/0.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	94 (T)

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.304	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Erosion**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Inflammation Acute**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	1/10 (10%)	9/10 (90%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	1/10.00	9/10.00	9/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	10%	90%	90%	100%	100%	100%
TERMINAL (d)	1/10 (10%)	9/10 (90%)	9/10 (90%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Metaplasia**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx  
Ulcer**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Larynx: Squamous Epithelium  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/10 (0%)	6/10 (60%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	6/10.00	4/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	60%	40%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	6/10 (60%)	4/10 (40%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P=0.033*	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P=0.033*	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.005**	P=0.043*	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P=0.007**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver  
Hepatodiaphragmatic Nodule**

**LESION RATES**

OVERALL (a)	0/10 (0%)	5/5 (100%)	2/2 (100%)	1/1 (100%)	1/1 (100%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	5/5.00	2/2.00	1/1.00	1/1.00	2/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	20%
TERMINAL (d)	0/10 (0%)	5/5 (100%)	2/2 (100%)	1/1 (100%)	1/1 (100%)	2/10 (20%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P=0.129N	P<0.001**	P=0.015*	P=0.091	P=0.091	P=0.227
POLY 1.5	P=0.129N	P<0.001**	P=0.015*	P=0.091	P=0.091	P=0.227
POLY 6	P=0.129N	P<0.001**	P=0.015*	P=0.091	P=0.091	P=0.227
COCH-ARM / FISHERS	P=0.269N	P<0.001**	P=0.015*	P=0.091	P=0.091	P=0.237
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P=0.066

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Liver  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	8/10 (80%)	0/5 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	8/10 (80%)
POLY-3 RATE (b)	8/10.00	0/5.00	0/2.00	0/1.00	0/1.00	8/10.00
POLY-3 PERCENT (g)	80%	0%	0%	0%	0%	80%
TERMINAL (d)	8/10 (80%)	0/5 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	8/10 (80%)
FIRST INCIDENCE	94 (T)	---	---	---	---	94 (T)

**STATISTICAL TESTS**

POLY 3	P=0.049*	P<0.001N**	P=0.053N	P=0.286N	P=0.286N	P=0.702
POLY 1.5	P=0.049*	P<0.001N**	P=0.053N	P=0.286N	P=0.286N	P=0.702
POLY 6	P=0.049*	P<0.001N**	P=0.053N	P=0.286N	P=0.286N	P=0.702
COCH-ARM / FISHERS	P=0.107	P=0.007N**	P=0.091N	P=0.273N	P=0.273N	P=0.709N
MAX-ISO-POLY-3	P=0.012*	P<0.001N**	P=0.023N*	P=0.089N	P=0.089N	P=1.000

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	9/10 (90%)
POLY-3 RATE (b)	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00	9/10.00
POLY-3 PERCENT (g)	100%	100%	100%	100%	100%	90%
TERMINAL (d)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	9/10 (90%)
FIRST INCIDENCE	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P=0.107N	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	P=0.107N	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	P=0.107N	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.105N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	P=0.041N*	(e)	(e)	(e)	(e)	P=0.158N

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung  
Metaplasia Osseous**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	1/10 (10%)	0/10 (0%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	2/10.00	1/10.00	0/10.00
POLY-3 PERCENT (g)	0%	0%	0%	20%	10%	0%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	1/10 (10%)	0/10 (0%)
FIRST INCIDENCE	---	---	---	94 (T)	94 (T)	---

**STATISTICAL TESTS**

POLY 3	P=0.649	(e)	(e)	P=0.227	P=0.500	(e)
POLY 1.5	P=0.649	(e)	(e)	P=0.227	P=0.500	(e)
POLY 6	P=0.649	(e)	(e)	P=0.227	P=0.500	(e)
COCH-ARM / FISHERS	P=0.647	(e)	(e)	P=0.237	P=0.500	(e)
MAX-ISO-POLY-3	P=0.149	(e)	(e)	P=0.066	P=0.158	(e)

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung: Alveolus  
Infiltration Cellular Histiocyte**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	8/10 (80%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	0/10.00	8/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	10%	0%	80%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	8/10 (80%)	10/10 (100%)
FIRST INCIDENCE	---	---	94 (T)	---	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	(e)	P=0.500	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	(e)	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.158	(e)	P<0.001**	P<0.001**



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Lung: Arteriole  
Mineralization**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	10%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	---	94 (T)

**STATISTICAL TESTS**

POLY 3	P=0.107	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	P=0.107	(e)	(e)	(e)	(e)	P=0.500
POLY 6	P=0.107	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.105	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.041*	(e)	(e)	(e)	(e)	P=0.158

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Goblet Cell  
Hyperplasia**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Olfactory Epithelium  
Inflammation**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium  
Accumulation, Hyaline Droplet**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Nose: Respiratory Epithelium  
Inflammation**

**LESION RATES**

OVERALL (a)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	10/10.00	10/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	100%	100%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
FIRST INCIDENCE	---	94 (T)	94 (T)	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**	P<0.001**

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Ovary  
Cyst**

**LESION RATES**

OVERALL (a)	0/10 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	1/1 (100%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	1/1.00	0/0.00	1/1.00	1/1.00	2/10.00
POLY-3 PERCENT (g)	0%	100%	0%	100%	100%	20%
TERMINAL (d)	0/10 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	1/1 (100%)	2/10 (20%)
FIRST INCIDENCE	---	94 (T)	---	94 (T)	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	(e)	P=0.091	(e)	P=0.091	P=0.091	P=0.227
POLY 1.5	(e)	P=0.091	(e)	P=0.091	P=0.091	P=0.227
POLY 6	(e)	P=0.091	(e)	P=0.091	P=0.091	P=0.227
COCH-ARM / FISHERS	P=0.411	P=0.091	(e)	P=0.091	P=0.091	P=0.237
MAX-ISO-POLY-3	(e)	P<0.001**	(e)	P<0.001**	P<0.001**	P=0.066

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Pancreas  
Atrophy**

**LESION RATES**

OVERALL (a)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
POLY-3 RATE (b)	2/10.00	0/0.00	0/0.00	0/0.00	0/0.00	0/10.00
POLY-3 PERCENT (g)	20%	0%	0%	0%	0%	0%
TERMINAL (d)	2/10 (20%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/10 (0%)
FIRST INCIDENCE	94 (T)	---	---	---	---	---

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.227N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.227N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.227N
COCH-ARM / FISHERS	P=0.132N	(e)	(e)	(e)	(e)	P=0.237N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.066N



**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN RATS(F344/N Tac)  
TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 mg/m3	25 mg/m3	50 mg/m3	100 mg/m3	200 mg/m3	400 mg/m3

**Trachea  
Inflammation Chronic**

**LESION RATES**

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	2/10.00	1/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	20%	10%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)	1/10 (10%)
FIRST INCIDENCE	---	---	---	---	94 (T)	94 (T)

**STATISTICAL TESTS**

POLY 3	P=0.086	(e)	(e)	(e)	P=0.227	P=0.500
POLY 1.5	P=0.086	(e)	(e)	(e)	P=0.227	P=0.500
POLY 6	P=0.086	(e)	(e)	(e)	P=0.227	P=0.500
COCH-ARM / FISHERS	P=0.089	(e)	(e)	(e)	P=0.237	P=0.500
MAX-ISO-POLY-3	P=0.059	(e)	(e)	(e)	P=0.066	P=0.158

**LEGEND**

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
  - (e) Value of Statistic cannot be computed.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at ( $P \leq 0.05$ ).
  - \*\* To the right of any statistical result, indicates significance at ( $P \leq 0.01$ ).
  - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.  
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*